

PUBLICATIONS [author(s) (in actual precedence of authorship); title; publisher or journal name; date (current year first); page numbers]

18. Books and monographs published: N/A

19. Juried or refereed journal articles and exhibitions:

1. **Richman, S.P.**, et al: Studies of Vicia faba root meristems irradiated with a negative pion beam. Rad. Res. Suppl. 7:283-289, 1967.
2. Izumi, A.K. and **Richman, S.P.**: Ectopic adrenocorticotrophic hormone syndrome. Arch. Dermatol. 102:555-559, 1970.
3. **Richman, S.P.**, Mavligit, G.M., Wolk, R., Gutterman, J.U. and Hersh, E.M.: Epilesional scarification: Preliminary report on a new approach to local immunotherapy. JAMA 234:1233-1235, 1975.
4. Gercovich, F.G., **Richman, S.P.** Rodriguez, V., Luna, M., McCredie, K.B., and Brodey, G.P. Successful control of systemic Aspergillus niger infections in two patients with acute leukemia Cancer 36:2271-2276, 1975.
5. Hersh, E.M., Gutterman, J.U., Mavligit, G.M., Reed, R.C., and **Richman, S.P.**: BCG vaccine and its derivatives. Potential practical considerations and precautions in human cancer immunotherapy. JAMA 235:646-650, 1976.
6. **Richman, S.P.**, Livingston, R.B., Gutterman, J.U., Suen, J.Y. and Hersh, E.M. Chemotherapy versus chemoimmunotherapy of head and neck cancer: Report of a randomized study. Cancer Treat. Rep. 60:535-539, 1976.
- 7.. Rodriguez, V., Richman, S.P., Benjamin, R.S., et al.: Phase II study with Baker's antifol in Solid tumors. Cancer Res. 37:980-983, 1977.
8. **Richman, S.P.**, Gutterman, J.U., Hersh, E.M. and Mavligit, G. M.: Phase I study of Immunotherapy with methanol extraction residue of BCG (MER). Cancer Treat. Repts. 61: 471-471, 1977
9. Schwarz, M.A., Gutterman, J.U., Hersh, E.M., **Richman, S.P.** and Mavligit, G.M. Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions. World J Surg. 1: 555-583, 1977.

10. Suen, J.Y., **Richman, S.P.**, Livingston, R.L., Hersh, E.M., Craig, R. and Tonymon, K. Results of the BCG adjuvant immunotherapy in 100 patients with epidermoid carcinoma of the head and neck. *Am. J. Surg.* 134:474-478, 1977.
11. Hortobagyi, G.N., **Richman, S.P.** Dandridge, K., Gutterman, J.U., Blumenschein, D.R. and Hersh, E.M.: Immunotherapy with BCG administration by scarification. Standardization of reactions and managements of side effects. *Cancer* 42:2293-2303, 1978.
12. Hortobagyi, G.N., Gutterman, J.U., Snyder, R.O., **Richman, S.P.** and Hersh, E.M. Pseudomonas vaccine: A phase I evaluation for cancer research. *Cancer Immunology and Immunotherapy* 4:201-207, 1978.
13. **Richman, S.P.**, Gutterman, J.U., Hersh, E.M. and Ribi, E.E.: Phase I-II study of intratumor immunotherapy with BCG cell wall skeleton plus P3. *Cancer Immunology and Immunotherapy* 5:41-44, 1978.
14. Issell, B.F., Valdevieso, M., Hersh, E.M., **Richman, S.P.**, Gutterman, J.U. and Bodey, G.P. Combination chemoimmunotherapy for extensive non-oat cell lung cancer. *Cancer Treat Rep.* 62:1059-1063, 1978.
15. **Richman, S.P.**, Gutterman, J.U. and Hersh, E.M.: Cancer Immunotherapy. *Canadian Medical Assoc. J.* 120:322-329, 1979.
16. Hortobagyi, G.N., Gutterman, J.U., Blumenschein, G.R., Tashima, C.K., Burgess, M.A., Einhorn, L., Buzdar, A.U., **Richman, S.P.** and Hersh, E.M.: Combination chemotherapy of metastatic breast cancer with 5-fluorouracil, Adriamycin and Cyclophosphamide, BCG. *Cancer* 43:1225-1233, 1979.
17. Blumenschein, G.R., Hortobagyi, G.N., **Richman, S.P.** et al: Alternating noncross resistant combination chemotherapy and active non-specific immunotherapy with BCG or MER-BCG for advanced breast carcinoma. *Cancer* 45:742-749, 1980.
18. Maroun, J.A., Quesada, J., Hersh, E.M., Gutterman, J.U., **Richman, S.P.** et al.: A phase I toxicity study of methanol extraction residue (MER) of Bacillus Calmette Guerin by intervenous route. *Cancer Treat. Rep.* 63:1781-1786, 1979.
19. **Richman, S.P.**, Gutterman, J.U. and Hersh, E.M.: Chemotherapy and Immunotherapy of malignant melanoma. *Compreh. Ther.* 6:57-61, 1980.

- 20 **Richman, S.**, Chism, V.T. and Murphy, S.G.: Effect of microbial fractions and vehicle on the survival of mice bearing the Lewis lung carcinoma. *Cancer Treat. Rep.* 64:1329-1333, 1980.
- 21 **Richman, S.P.**, Hersh, E.M., Gutterman, J.U., Rios, A., Hortobagyi, G.N., Blumenschein, G.R. and Rib, E.E. Administration of BCG cell wall skeleton into malignant effusions. Toxic and therapeutic effects. *Cancer Treat. Rep.* 65:383-387, 1981.
- 22 Richman, S.P., Chism, V.T. and Murphy, S.G.: Augmentation of ADCC in mice by microbial fractions. *Cancer Immunol. Immunother.* 11:233-238, 1981.
23. Valdivieso, M., Richman, S., Burgess, A.M. et al.: Initial clinical studies of vindesine. *Cancer Treat. Rep.* 65:873-875, 1981.
24. Feun, L.G., Jordan, G., Burgess, M.A., Hersh, E.M., Mavligit, G., McBride, C.M., Benjamin, R.S. and Richman, S.P., et al.: The Natural History of Resectable Metastatic Melanoma (Stage IVA Melanoma). *Cancer* 50:1656-1663, 1982.
25. Blijham, G.H., Barlogie, B. and Richman, S. Et al: Medulloblastoma and neuroblastoma in adults. *Neth. J. Med.* 25 (4):94-99, 1982.
26. Woodcock, T.M., Blumenreich, M.S., Richman, S.P. Kubota, T.T., Gentile, P.S. and Allegra, J.C.: Combination Chemotherapy with Cis-Diamminedichloroplatinum and Vinblastine in Advanced Non-Small Cell Lung Cancer. *J. Clin. Oncology.* 1:247-250, 1983.
27. Allegra, J.C., Woodcock, T.M., Richman, S.P., Bland, K.I. and Witliff, J.L.: A Phase II Trial of Tamoxifen, Premarin, Methotrexate and 5-Fluorouracil in Metastatic Breast Cancer. *Breast Cancer Treat. and Res.* 2:93-99, 1982.
28. Richman, S.P., Woodcock, T. M., Kubota, T.T., Blumenreich, M.S., Gentile, P.S. and Allegra J.C.: A Phase II Trial of Vinblastine, Bleomycin and Cisplatin (VBP) Followed by Decarbazine and Mitolactol in Metastatic Melanoma. *Cancer Treat. Repts.* 68:1395-1396, 1984.
29. Blumenreich, M.S., Woodcock, T.M., Jones, M., Richman, S.P. et al.: High-dose cisplatin diamminedichloroplatinum II in patients with advanced malignancies. *Cancer* 55:1118-1122, 1985.

30. Blumenreich, M.S., Woodcock, T.M., Richman, S.P, et al.: A Phase I trial of Dactinomycin intravenous infusion in patients with advanced malignancies. *Cancer* 56:256-258, 1985.
31. Blumenreich, M.S., Woodcock, T.M., Gentile, P.S., Barnes, G.R., Jose, B., Sherrill, E.J., Richman, S.P., et al. High-Dose cisplatin and vinblastine infusion with or without radiation therapy in patients with advanced non-small cell lung cancer. *J. Clin. Oncol.* 5:1725-1730, 1987.
32. Sridhar, K.S., Bounassi M.J., Raub, W., and Richman, S.P.: Clinical features of adenosquamous lung carcinoma in 127 patients. *Am. Rev. Respir. Dis.* 142:19-23, 1990.
33. Sridhar, K.S., Samy, T.S.A., Agarwal, R.P., Duncan, R.C., Benedetto, P., Krishan, A.G., Vogel, C.L., Feun, L.G., Savaraj, N.M., Richman, S.P. and Zubrod, C.G. A Phase I study of 4'-O-Tetrahydropyranlyladiamycin. *Cancer* 66:2082-2091, 1990.
34. Feun, L.G., Savaraj, N., Benedetto, P., Hanlon, J., Sridhar, K.S., Collier, M., **Richman, S.**, Liao, S.H., and Clendennin, N.J. Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies. *J. Natl. Cancer Inst.* 83: 51-55, 1991.
35. Ardalan, B, Chua, L., Tian, E., Reddy, R., Sridhar, K.S., Benedetto, P., **Richman, S.** et al. A Phase II study of weekly 24 hour infusion with high-dose Fluorouracil with Leucovorin in colorectal carcinoma. *J. Clin Oncol* 9: 625-630, 1991.
36. Sridhar, K., Hussein, A., Benedetto, P., Waldman, S., Feun, L., Savaraj, N., and **Richman S.** Phase II Trial of Mitoxantrone in Head and Neck Carcinoma. *Am. J. Clin. Oncol.* 14:298-304, 1991.
37. Ardalan, B., Sridhar K.S., Benedetto, P., **Richman, S.**, Waldman, S., Morrell, L., Feun, L., Savaraj, N., Fodor, M., Livingstone, A. A Phase I, II Study of High Dose 5-Fluorouracil and High Dose Leucovorin with Low Dose Phosphonacetyl-L-Aspartic Acid in Patients with Advanced Malignancies. *Cancer* 68:1242-1246, 1991.
38. Sridhar K.S., Raub, Jr., W., Duncan R.C., Hilsenbeck S., and **Richman S.P.** Lung carcinoma in 1,336 patients. *Am. J. Clin. Oncol.* 14:496-508, 1991.
39. Gucaip R, Ritch P, Wiernik PH, Sarma PR, Keller A, **Richman SP,**

- Tauer K, Neidhart J, Mallette LE, Siegel R and VandePol CJ. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. *J. Clin. Oncol.* 10:134-142, 1992.
40. Ardalan, B., Sridhar, K., Reddy, R., Benedetto, P., **Richman, S.**, Waldman, S., Morrell, L., Feun, L., Savaraj, N., and Livingstone, A. Phase I study of high dose 5-fluorouracil and high dose leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. *Int. J. Radiation Oncology Biol. Phys.* 22: 511-514, 1992.
 41. Ardalan B., Ucar A., Reddy R, Livingstone AS, Markoe A, Schwade J, **Richman SP**, Donofrio K. Phase I trial of low dose N-Phosphonacetyl-L-Aspartic Acid and High dose 5-Fluorouracil administered concomitantly with Radiation Therapy for Unresectable Localized Adenocarcinoma of the Pancreas. *Cancer*, 74:7, 1994.
 42. Hantel, A., Tangen, C.M., Macdonald, J.S., **Richman, S.P.** et al. Phase II trial of trimetrexate in untreated advanced gastric carcinoma. *Invest. New Drug* 12:155-157, 1994.
 43. Feun L.G., Savaraj, N., Moffat, F., Robinson, D., Liebmann, A., Hurley J., Raub, Jr.,W.A. and **Richman, S.P.** Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC, and tamoxifen in advanced malignant melanoma. *Melanoma Res.* 5: 273-276, 1995.
 44. Whitehead R.P., Wolf, M.K., Solanski, D.L., Hemstreet, G.P., Benedetto, P., **Richman, S.P.** et al. A phase II trial of continuous infusion recombinant interleukin-2 in patients with advanced renal cell carcinoma: A Southwest Oncology Group Study. *J. Immunotherapy* 18: 104-114, 1995.
 45. Martino, R.L., Fleming, T.R., Morrell, L.M., Ardalan,B., **Richman, S.P.**, and Macdonald, J.S. Phase II trial of low dose N-(phosphonacetyl)-disodium-L-aspartic acid and high-dose 24-hour infusional 5-Fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group Study. *Invest. New Drugs* 14:419-421, 1996.
 46. Morrell, L.E., Lee, Y.J., Hurley, J., Arias, M., Mies,C., **Richman, S.P.**, Hernandez, H., Donofrio K., Raub, Jr.,W.A., and Cassileth, P.A. A phase II trial of neoadjuvant methotrexate, vinblastine,doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma. *Cancer* 82:503-511, 1998.

47. Anderson, K.O. Mendoza, T.R., Valero, V., **Richman, S.P.**, et al. Minority Cancer Patients and their Providers. Pain management attitudes and practice. *Cancer* 88:1929-1938, 2000.
48. Anderson, K.O., **Richman,S.P.**, Hurley, J., et. al. Cancer pain management among minority patients: Perceived needs and barriers to optimal control. *Cancer* 94: 2295-2304, 2002.
49. Anderson, K.O., Mendoza, T.R., Payne, R., Valero, V., Palos, G.R., Nazario,A., **Richman,S.P.**,et.al. Pain education for underserved minority cancer patients: A randomized controlled trial. *J. Clini. Oncology*. 22:4918 – 4925, 2004.

ABSTRACTS

1. **Richman, S.P.**: Phase I study of Immunotherapy with methanol extraction residue of BCG (MER). *Proc. Amer. Soc. Clin. Oncol.* 16:1025, 1975.
2. Rodriguez, V., **Richman, S. P.**, Benjamin, R.S. et al.: Phase II studies of Baker's antitumor. *Proc. Amer. Assoc. Cancer Res.* 17:60, 1976.
3. **Richman, S.P.**, Gutterman, J.U., Hersh, E.M. and Price, H.R.: Phase I study of intratumor immunotherapy with BCG cell wall skeleton plus P3. *Proc. Amer. Soc. Clin. Oncol.* 18:351, 1977.
4. **Richman, S. P.**, Murphy, S., Hersh, E.M., Gutterman, J.U. and Ribi, E.: Toxicity in mice of BCG wall skeleton, trehalose dimycolate and mutant endotoxin attached to oil droplets. *AFCR* 26:36A, 1978.
5. **Richman, S.P.**, Hortobagyi, G.N., Gutterman, J.U., Hersh, E.M., Mavligit, G. and Dale, S. Toxicity of BCG administered by scarification to cancer patients. *Am. Soc. Clin. Oncol.* 19:449, 1978.
6. **Richman, S.P.**, Chism, V. and Murphy,S.: Vehicle and microbial fractions interact to prolong survival of mice with Lewis lung carcinoma. *Amer. Assoc. Cancer Res.* 20:144, 1979.
7. Murphy, S., **Richman, S.**, and Hersh, E.: Immunological unresponsiveness in treated leukemic guinea pigs. *Amer. Assoc. Cancer Res.* 20:170, 1979.
8. **Richman, S.P.**, Hortobagyi, G.N., Legha, S.S., et al.: Prognostic significance of pleural effusion in patients with metastatic breast

- carcinoma treated with systemic chemotherapy. Proc. Amer. Assoc. Cancer Res. 21: 170, 1980.
9. Allegra, J.C., Woodcock, T.M., **Richman, S.P.**, Patel, J.D. and Wittliff, J.L.: A Phase II Evaluation of Tamoxifen, Premarin, Methotrexate (MTX) and 5-Fluororacil (5-FU) in Stage IV Breast Cancer. Am. Soc. Clin. Oncol. 22:441, 1980.
 10. Woodcock, T.M., Allegra, J.C., **Richman, S.P.**, Horowitz, J.A., and Snider, H.L.A Phase II Evaluation of Vinblastine (VLB) and Diamminedichloroplatinum II (DDP) in Non-Small Cell Cancer of the Lung. Am. Soc. Clin. Oncol. 22:501, 1981
 11. **Richman, S.P.**, Tatum, K. and Richman, K. (SPON: William J. Waddell): Monocyte Cytotoxicity Assay in Normal Donors. American Society of Pharmacology and Experimental Therapeutics and the Society of Toxicology, May, 1982.
 12. **Richman, S.P.**, Woodcock, T.M., Lalley, K., Tatum, K., and Spalding, S: Doxorubicin Concentrations in Human Mononuclear Cells Following Therapy. Am. Soc. of Clin. Oncol., December, 1982.
 13. **Richman, S.P.**, Tatum, K., Stadig, B., and Richman, K.: Ammonia Exposure In Vitro Depresses Monocyte Cytotoxicity. Am. Assoc. for Cancer Res., December, 1982.
 14. **Richman, S.P.**, Woodcock, T. M., Lalley, K. et al.: Doxorubicin Concentrations in Human Mononuclear Cells Following Therapy. Proceeding A.S.C.O. 2:247-250, 1983.
 15. **Richman, S.P.**, Tatum, K., Stadig, B., et al.: Ammonia Exposure In Vitro Depresses Monocyte Cytotoxicity. Proceeding A.A.C.R. 24:210, 1983.
 16. Blumenreich M.S, Woodcock, T.M., Jones, M.K., **Richman, S.P.**, Gentile, P.S., Kubota, T.T. and Allegra, J.C.: High-Dose Cisplatin (DDP) in Patients (PTS) with Advanced Malignancies. Proc. Am. Assoc. for Clin. Res. May, 1984.
 17. Blumenreich, M.S., Woodcock, T.M., **Richman, S.P.**, Gentile, P.S., Kubota, T.T., Greenwell, S.K., Jones, M.K. and Allegra, J.C.: High Dose Cisplatin (DDP) and Vinblastine (VLB) Infusion in Advanced Non-Small Cell Lung Cancer (NSCLC). Proc. Am. Soc. of Clin. Oncol. 3:231, 1984.

18. **Richman, S.P.**, Lopez-Bernstein, G., Woodcock, T.M., Lalley, K. and Perez-Soler, R. Pharmacology of Doxorubicin Uptake into Human Monocytes In Vitro Proc. Am. Assoc. of Cancer Res. 25:163, 1984.
19. Woodcock, T.M., Allegra, J.C., **Richman, S.P.**, Blumenreich, M.S., Kubota, T.T., Gentile, P.S., Lalley, K.A., Jones, M.K., Greenwell, S.K.: Pharmacology and Phase I Trial of Weekly Daunorubicin (DNR). Proc. Am. Soc. of Clin. Oncol. 3:42, 1984.
20. Fischl, M., Lucas, S., **Richman, S.**, Koch, G.: Phase II study of Wellferon and Vincristine in AIDS related Kaposi's sarcoma. Proc. Am. Soc. Onc. 6:2, 1987.
21. Feun, L., Clendenin, N.J., Savaraj, N., Benedetto, P., Sridhar, K., Hanlon, J., Collier, M. and **Richman, S.** Phase I trial of Piritrexim capsules using prolonged low dose administration. Pro. AACR, 1988.
22. **Richman, S.P.**, Smith, D., Hilsenbeck, S., and East, D.: Review of Cases of Breast Carcinoma at University of Miami/Jackson Memorial Hospital. American Cancer Society, Florida Division: Proc. Twelfth Annual Cancer Research Seminar for the Researchers of Florida, Abstract #27, 1989.
23. Hussein, A., Ardalan, B., Shanahan, W., Aspinall, R., Gardiner, P., Shield, M., **Richman, S.**, Benedetto, P., Feun, L., Waldman, S., Glantz, A., Sklaver, L., and Sridhar, K: Phase I Continuous (Cont.) Intravenous (IV) Infusion of Carbetimer (CBT) in Refractory Malignancies. American Cancer Society, Florida Division: Proc. Twelfth Annual Cancer Research Seminar for the Researchers of Florida, Abstract #31, 1989.
24. Hussein, A., Ardalan, B., Sklaver, L., Reddy, R., Savaraj, N., Waldman, S., **Richman, S.**, Feun, L., Hung, S., Benedetto, P., and Sridhar, K.: Chemotherapy (C) of Advanced Carcinomas (Ca) with 5-Fluorouracil and Leucovorin (LV). American Cancer Society, Florida Division: Proc. Twelfth Annual Cancer Research Seminar for the Researchers of Florida, Abstract #35, 1989.
25. Hung, S., Savaraj, N., Reddy, R., Jeffers, L., Schiff, E., Waldman, S, and **Richman, S.** Tamoxifen in the Treatment of Hepatocellular Carcinoma (HCC). Proceedings of the American Cancer Society, Florida Division: Proc. Twelfth Annual Cancer Research Seminar for the Researchers of Florida, Abstract #428, 1989.
26. Hung, S., Savaraj, N., Reddy, R., Jeffers, L., Schiff, E., Waldman, S., and **Richman, S.** Tamoxifen in the Treatment of Hepatocellular

- Carcinoma (HCC). Proc.Am. Soc. of Clin.Oncol. 8:110, 1989.
27. Ardalan, B., Hussein, A., Sklaver, L., Reddy, R., Benedetto, P., Sridhar, K .**Richman, S.** Feun, L.,Savaraj, N., Waldman, S., and Hung, S. Chemotherapy (C) of Advanced Carcinoma(Ca) with 5-Fluorouracil (FU) and Leucovorin (LV).Proc. Am. Soc. of Clin. Oncol 8:116, 1989.
 28. Sridhar, K., Hussein, A., Barmann, A., Benedetto, P., Ardalan, B., Waldman,S., **Richman,S,** Feun, L., Savaraj, N., Morrell, L., and Donnelly, E.: Phase II Study of Q3 Week IV Bolus Pirarubicin (4'-O-Tetrahydropyranyl)adriamycin) in Head and Neck Carcinoma (H & N Ca). Proc. Am. Soc. of Clin.Oncol. 9:179, 1990.
 29. Waldman, S., Sridhar, K., **Richman, S.**, East D., Berlin, N., Vogel, C., Salewski, E.:Phase II Trial of Pirarubicin (P) in Advanced Breast Ca (BC).Proc. Am. Soc. of Clin. Oncology. 9:50, 1990.
 30. Chua, L., Ardalan, B., Sridhar, K.S., Hussein, A., **Richman, S.** et al. A Phase II Study of Short Term Protracted Infusion with High Dose 5-Fluorouracil with Leucovorin inColorectal Carcinoma. Proc. ASCO 9:104, 1990.
 31. Morrell, L., Ardalan, B., **Richman, S.**, et al. A phase II Study of Thiotepa in Combination with 5-fluorouracil and Leucovorin in Patients with Advanced Breast Cancer Proc of ASCO 10:62, 1991.
 32. Sridhar, K.S., Krishan A., Anac, S., Duncan, R., Benedetto, P., Ardalan, B., Samy,T., Feun, L., Savaraj, and **Richman,S.** Phase I Study of Doxorubicin plus Prochlorperazine as a Resistance Modifiere. Proc. ASCO 10: 106, 1991.
 33. Ardalan, B., Sridhar, K., **Richman, S.**, et al. Addition of HJigh Dose Leucovorin to High Dose Infusion of 5-fluorouracil and Low Dose PALA: Effective in Pancreatic Cancer Therapy. Proc. ASCO 10: 139, 1991.
 34. Sridhar, K.S., Raub, Jr., W.A., Smith, D., and **Richman, S.** Lung Cancer: Recent Trends in Smoking History in Lung Cancer Patients. Proc. ASCO 10: 249, 1991.
 35. Flores M.R., Cassileth, P., Pozo, C., Sumrall E., Bean, J., Morrell, L., Hurley J., Love, N.,Trapido, E., **Richman, S.** Assessment of socio economic, cultural health care diversity and patient characteristics in breast cancer patients: an interim analysis. Proc ASCO 13:454, 1994.

36. Ardalan, B., Ucar, A., Reddy, R., Livingstone, A., Schwade, J., Markoe, A., **Richman, S.** Phase I trial of low dose PALA and high dose 5-fluorouracil (5-FU) as a short-term infusion concomitantly with radiation therapy in the treatment of adenocarcinoma of the pancreas.
37. Ardalan, B., Donofrio, K., Livingstone, A., Reddy, R., **Richman, S.** et al. A phase II study of weekly low dose bolus phosphonacetyl-L-aspartic acid (PALA) and 24 hr infusion with high dose fluorouracil (FU) with leucovorin (LV) in colorectal cancer. Proc. ASCO 14:220, 1995.
38. Morrell, L.E., Lee, Y.J., Hurley, J., Arias, M., **Richman, S.P.**, Cassileth, P.A. Phase II Trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of locally advanced breast cancer Proc ASCO 16:643, 1997.
39. Ardalan, B., Sparling, L., Livingstone, A., Francheschi, D., Sridhar, K.S., Feun, L.G. **Richman, S.P.**, Triplett, N. Phase II trial of high-dose 24-hour Infusion of 5-fluorodeoxyuridine in patients with inoperable pancreatic cancer (previously failed 5-FU and Gemzar). Proc. ASCO 16 999, 1997

Other works and publications:

1. Gutterman, J.U., Mavligit, C.M., Reed, R.C., **Richman, S.P.**, McBride, C.M. and Hersh, E.M.: Immunology and immunotherapy of malignant melanoma: Historic review and perspectives for the future. Sem. Onc. 2:155-184, 1975.
2. Hersh, E.M., Mavligit, G.M. Gutterman, J.U. and **Richman, S.P.** .Immunotherapy of human cancer. In: Cancer, A Comprehensive Treatise F.F. Becker, Editor, pp. 425-532, Plenum Press, New York, 1977.
3. Gutterman, J.U., Mavligit G.M. McBride, G.M., **Richman, S.P.**, Burgess, M.A. and Hersh, E.M.: Postoperative immunotherapy for recurrent melanoma: An updated report. In Immunotherapy of Cancer: Present Status of Trials in Man. Raven Press, New York 35-56, 1977.
4. Gutterman, J.U., Mavligit, G. M., **Richman, S.P.**, Burgess, M.A. and Hersh, E.M.: Chemoimmunotherapy of disseminated malignant melanoma with BCG: Followup report. In: Immunotherapy of Cancer: Present Status of Trials in Man. Raven Press, New York, 103-112, 1977.

5. Hortobagyi, G.N., Gutterman, J.U., Blumenschein, G.R., Buzdar, A., Burgess, M.A., **Richman, S.P.**, Tashima, C.K., Schwarz, M. and Hersh, E.M.: Chemoimmunotherapy of Advanced Breast Cancer with BCG. In: Immunotherapy of Cancer: Present Status of Trials in Man. New York, Raven Press, 1977, pp. 655-663.
6. Hortobagyi, G.N., Gutterman, J.U., Blumenschein, G.R., Buzdar, A.U., **Richman, S.P.**, Wiseman, C. and Hersh, E.M.: Immunotherapy and chemotherapy for human breast cancer. In: Immunotherapy of Cancer: Present Status of Trials in Man. Raven Press, New York, 321-345, 1978.
7. Gutterman, J.U., Mavligit, G.M. and **Richman, S.P.** et al.: Immunotherapy for malignant melanoma. In: Immunotherapy of Human Cancer. Raven Press, New York, 257-265.
8. Gutterman, J.U., **Richman, S.P.**, Mc Bride, C.M. et al.: Immunotherapy for recurrent malignant melanoma: Efficacy of BCG in prolonging the postoperative disease-free interval and survival. In: Recent Results Cancer Research 68:359-362, 1979.
9. **Richman, S.P.**, Gutterman, J.U., Hersh, E.M. and Mavligit, G.M.: Immunotherapy of cancer in man. CRC Press for Handbook in Clinical Laboratory Science 335-363, 1979.
10. **Richman, S.P.**, Hersh, E.M., Gutterman, J.U. and Mavligit, G.M.: Immune depression in cancer patients: Cell-mediated immunity. CRC Press for Handbook in Clinical Laboratory Science 379-404, 1979.
11. Hortobagyi, G.N., Gutterman, J.U., Blumenschein, G.R., Buzdar, A., Burgess, M.A., **Richman, S.P.**, Tashima, C.K., Schwartz, M. and Hersh, E.M.: Chemoimmunotherapy of advanced breast cancer with BCG. In: Recent Results in Cancer Research. 62:143-150, 1979.
12. **Richman, S.P.**, Hersh, E.M., Gutterman, J.U. et al.: Phase I-II Study of immunotherapy of malignant effusions with BCG cell wall skeleton-P3. The Fifth Chicago Symposium. Cancer Immunology Experimental and Clinical. Crispen (Ed.) Elsevier North Holland, Inc., 473-479, 1980.
13. Woodcock, T.M., Allegra, J.C., **Richman, S.P.**, Lalley, K., Kubato, T.T., Blumenreich, M.S., Gentile, P., Jones, M. and Seeger, J.: Pharmacology and Phase I Clinical Studies of Daunorubicin in Patients with Advanced Malignancies. Seminars in Oncology II:28-32, 1984.

14. Seeger, J., **Richman, S.P.**, Allegra, J.C.: Systemic therapy of malignant melanoma Med. Clin. N. Amer. 70:89-94, 1986.
15. **Richman, S.P.** and Vogel, C.L. Kaposi's sarcoma in Current Therapy in Hematology-Oncology-Brain, M.C. and Carbone, P. P. eds., pp. 353-355, 1988.